Nautilus Biotechnology

Nautilus Biotechnology is developing a single-molecule protein analysis platform to quantify human proteome. By doing so, the company intends to improve the speed and success rate of therapeutic development, particularly personalized and predictive medicine. In addition, the company claims the platform can also identify biomarkers to enable new diagnostics. 

Founded in 2016, the company’s focus is on the field of proteomics with technology that incorporates the preparation of a protein array that identifies and quantifies millions of protein molecules collected from blood, tissue or cells. The platform will also decode and analyze the protein molecules and their individual properties. The company’s database of protein molecules will improve with the database growing with more proteome information. 

Key customers and partnerships

In December 2020, Nautilus formed a collaboration with the pharma giant Roche’s subsidiary, Genentech, to utilize the company’s technology to analyze and map the various forms of a particular protein. 

Funding and financials

In July 2021, the company went public on Nasdaq via a special-purpose acquisition company (SPAC), under the ticker symbol “NAUT”, and raised USD 345 million. For FY2023 , the company reported a net loss of USD 63.7 million, a 10% decrease YoY.